Untitled Bingo - Call List

(Print) Use this randomly generated list as your call list when playing the game. There is no need to say the BINGO column name. Place some kind of mark (like an X, a checkmark, a dot, tally mark, etc) on each cell as you announce it, to keep track. You can also cut out each item, place them in a bag and pull words from the bag.

1. Healthcare Professional
2. Quality Management System (QMS)
3. Monitoring Plan
4. Literature Report
5. periodic safety update report (PSUR)
6. Blinding or Masking
7. Global Patient Safety
8. Causality Assessment
9. Individual Case Safety Report (ICSR)
10. Good Clinical Practice
11. background rates
12. New Drug Application
13. Risk-Benefit Balance
14. Adverse Event of Special Interest (AESI)
15. Investigator
16. Suspected Unexpected Serious Adverse Reaction (SUSAR)
17. Medical Review
18. Patient Safety
19. Off-label use
20. Drug Product
21. Company Safety Committee
22. Data Lock Point
23. Spontaneous (Unsolicited) report
24. Post-Marketing Surveillance
25. Investigator’s Brochure
26. Chief Safety Officer
27. World Health Organization
28. Aggregate Safety Report (ASR)
29. Periodic Safety Update Report
30. Pharmacovigilance System Master File
31. Signal Detection
32. Solicited reports
33. Good Pharmacovigilance Practice
34. Medical Dictionary for Regulatory Activities (MedRA)
35. Product Safety Strategy
36. Business Continuity Plan
37. Interventional Study
38. International Conference on Harmonization (ICH)
39. National Medical Product Administration
40. Country Safety Lead/Manager
41. Drug Substance
42. Signal Detection Plan
43. Adverse Drug Reaction (ADR)
44. Council for International Organizations of Medical Sciences
45. Safety Management Team
46. PV Agreement
47. Quality Assurance
48. Expectedness
49. Identified Risk
50. Dear Investigator Letter
51. Safety Data Exchange Agreement
52. Health Authority
53. Organized Data Collection Program
54. Post-authorization Safety Study
55. Company Core Data Sheet
56. Reference Safety Information
57. Validated Signal
58. Pharmacovigilance
59. Occupational exposure
60. Non-validated signal
61. process excellence
62. Important Potential Risks
63. Serious Adverse Event
64. alliance management
65. Pharmacovigilance System
66. Affiliate
67. Drug Adverse Event Reporting System
68. Tolerability
69. Clinical Trial Application
70. Company Core Safety Information
71. Refuted Signal
72. Side effect
73. Signal Validation
74. Clinical Study Number
75. Overdose
76. Corrective and Preventive Action (CAPA)
77. GVP Module I
78. Development Safety Update Report
79. Protocol
80. Urgent Safety Measure
81. Non-Interventional Study
82. Clinical Development Program
83. Unexpected Events
84. Signal Assessment
85. Informed Consent
86. Developmental Risk Management Plan
87. Global Safety Database
88. Investigational Medicinal Product
89. EudraVigilance
90. Institutional Review Board
91. Other Safety Issue
92. Marketing Authorization Holder
93. Pharmacovigilance
94. Risk Management Plan
95. Safety Signal
96. Observational study
97. Listedness/ expectedness
98. Clinical Trial
99. Adverse Event Report Number
100. Product Quality Complaint
101. Special Situations
102. Sponsor
103. Adverse Event (AE)
104. Periodic Benefit-Risk Evaluation Report
105. Safety Assessment Team
106. Subject Matter Expert
107. Safety Information
108. Local Safety Representative
109. Signal Prioritization
110. Contract Research Organization (CRO)
111. Non-serious AESI
112. Comparator Product
113. Drug Abuse
114. Risk Communication
115. Product Recall
116. Signal Management Process
117. Development International Birth Date
118. BeiGene Representative
119. Benefit-risk analysis
120. Individual Case Safety Report
121. Business Partner
122. Labeled or unlabeled
123. Risk Management
124. Investigational New Drug Application
125. Medicines and Healthcare Regulatory Agency
126. Qualified Person for Pharmacovigilance
127. Product
128. Pharmacoepidemiology
129. Clinical Study
130. Regulatory authority